BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25270337)

  • 1. [Andersen-Tawil syndrome: a review of its clinical and genetic diagnosis with emphasis on cardiac manifestations].
    Márquez MF; Totomoch-Serra A; Vargas-Alarcón G; Cruz-Robles D; Pellizzon OA; Cárdenas M
    Arch Cardiol Mex; 2014; 84(4):278-85. PubMed ID: 25270337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kir 2.1 channelopathies: the Andersen-Tawil syndrome.
    Tristani-Firouzi M; Etheridge SP
    Pflugers Arch; 2010 Jul; 460(2):289-94. PubMed ID: 20306271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrocardiogram in Andersen-Tawil syndrome. New electrocardiographic criteria for diagnosis of type-1 Andersen-Tawil syndrome.
    Kukla P; Biernacka EK; Baranchuk A; Jastrzebski M; Jagodzinska M
    Curr Cardiol Rev; 2014 Aug; 10(3):222-8. PubMed ID: 24827800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry.
    Barajas-Martinez H; Hu D; Ontiveros G; Caceres G; Desai M; Burashnikov E; Scaglione J; Antzelevitch C
    Circ Cardiovasc Genet; 2011 Feb; 4(1):51-7. PubMed ID: 21148745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7).
    Tsuboi M; Antzelevitch C
    Heart Rhythm; 2006 Mar; 3(3):328-35. PubMed ID: 16500306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1.
    Kokunai Y; Nakata T; Furuta M; Sakata S; Kimura H; Aiba T; Yoshinaga M; Osaki Y; Nakamori M; Itoh H; Sato T; Kubota T; Kadota K; Shindo K; Mochizuki H; Shimizu W; Horie M; Okamura Y; Ohno K; Takahashi MP
    Neurology; 2014 Mar; 82(12):1058-64. PubMed ID: 24574546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and functional characterisation of a novel KCNJ2 mutation, Val302del, causing Andersen-Tawil syndrome.
    Ördög B; Hategan L; Kovács M; Seprényi G; Kohajda Z; Nagy I; Hegedűs Z; Környei L; Jost N; Katona M; Szekeres M; Forster T; Papp JG; Varró A; Sepp R
    Can J Physiol Pharmacol; 2015 Jul; 93(7):569-75. PubMed ID: 26103554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [QTU pattern in a patient with the Anderson-Tawil syndrome].
    Ciurzyński M; Bienias P; Kostera-Pruszczyk A; Pruszczyk P
    Kardiol Pol; 2010 Mar; 68(3):339-41; discussion 342. PubMed ID: 20411461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Andersen-Tawil syndrome: clinical and molecular aspects.
    Nguyen HL; Pieper GH; Wilders R
    Int J Cardiol; 2013 Dec; 170(1):1-16. PubMed ID: 24383070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype.
    Limberg MM; Zumhagen S; Netter MF; Coffey AJ; Grace A; Rogers J; Böckelmann D; Rinné S; Stallmeyer B; Decher N; Schulze-Bahr E
    Basic Res Cardiol; 2013 May; 108(3):353. PubMed ID: 23644778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel de novo mutation in the KCNJ2 gene in a patient with Andersen-Tawil syndrome.
    Kim JB; Chung KW
    Pediatr Neurol; 2009 Dec; 41(6):464-6. PubMed ID: 19931173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A new type of periodic paralysis: Andersen-Tawil syndrome].
    Pouget J
    Bull Acad Natl Med; 2008 Nov; 192(8):1551-6; discussion 1556-7. PubMed ID: 19445372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KCNJ2 variant of unknown significance reclassified as long QT syndrome causing ventricular fibrillation.
    Obeyesekere MN; Klein GJ; Conacher S; Krahn AD
    Can J Cardiol; 2011; 27(6):870.e11-3. PubMed ID: 21875779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiological mechanisms of ventricular arrhythmias in relation to Andersen-Tawil syndrome under conditions of reduced IK1: a simulation study.
    Sung RJ; Wu SN; Wu JS; Chang HD; Luo CH
    Am J Physiol Heart Circ Physiol; 2006 Dec; 291(6):H2597-605. PubMed ID: 16877549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Andersen-Tawil syndrome: report of 3 novel mutations and high risk of symptomatic cardiac involvement.
    Kostera-Pruszczyk A; Potulska-Chromik A; Pruszczyk P; Bieganowska K; Miszczak-Knecht M; Bienias P; Szczałuba K; Lee HY; Quinn E; Ploski R; Kaminska A; Ptáček LJ
    Muscle Nerve; 2015 Feb; 51(2):192-6. PubMed ID: 24861851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the KCNJ2 Mutation in a Korean Family with Andersen-Tawil Syndrome and Developmental Delay.
    Kim NR; Jang JH; Jeon GW; Cho EH; Sin JB
    Ann Clin Lab Sci; 2016; 46(1):110-3. PubMed ID: 26927354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome.
    Ballester LY; Benson DW; Wong B; Law IH; Mathews KD; Vanoye CG; George AL
    Hum Mutat; 2006 Apr; 27(4):388. PubMed ID: 16541386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and clinical characterization of a mutation in KCNJ2 associated with Andersen-Tawil syndrome.
    Lu CW; Lin JH; Rajawat YS; Jerng H; Rami TG; Sanchez X; DeFreitas G; Carabello B; DeMayo F; Kearney DL; Miller G; Li H; Pfaffinger PJ; Bowles NE; Khoury DS; Towbin JA
    J Med Genet; 2006 Aug; 43(8):653-9. PubMed ID: 16571646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a novel KCNJ2 sequence variant detected in Andersen-Tawil syndrome patients.
    Scheiper S; Hertel B; Beckmann BM; Kääb S; Thiel G; Kauferstein S
    BMC Med Genet; 2017 Oct; 18(1):113. PubMed ID: 29017447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management and treatment of Andersen-Tawil syndrome (ATS).
    Sansone V; Tawil R
    Neurotherapeutics; 2007 Apr; 4(2):233-7. PubMed ID: 17395133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.